Evidence map›Paper›PMID 25632808›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2015

Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease.

Lucy M Almers, James E Graham, Peter J Havel, Douglas A Corley

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Association of Serum Levels of Adipokines and Insulin With Risk of Barrett's Esophagus: A Systematic Review and Meta-Analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2015
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Adiponectin level changes among Egyptians with gastroesophageal reflux disease.JGH open : an open access journal of gastroenterology and hepatology · 2018
    Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Lucy M AlmersDivision of Research, Kaiser Permanente, Oakland, California.
James E GrahamDepartment of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, California; Department of Nutrition, University of California, Davis, California.
Peter J HavelDepartment of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, California; Department of Nutrition, University of California, Davis, California.
Douglas A CorleyDivision of Research, Kaiser Permanente, Oakland, California. Electronic address: Douglas.Corley@kp.org.
Kaiser Permanente · USUniversity of California, Davis · US

Funding

Epidemiology and Incidence of Barrett's EsophagusR01DK063616 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI CORLEY, DOUGLAS ALLEN · 2002 to 2010
$2.6M
Adipokines and Barrett's EsophagusR56DK087748 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI CORLEY, DOUGLAS ALLEN · 2010 to 2010
$767k
NIDDK NIH HHS R01 DK063616NIDDK NIH HHS R01 DK63616NIDDK NIH HHS R56 DK087748
6 · The paper itself

Abstract

BACKGROUND &

aimsAbdominal obesity and increasing body mass index are risk factors for esophageal adenocarcinoma and its main precursor, Barrett's esophagus; however, there are no known biological mechanisms for these associations or regarding why only some patients with gastroesophageal reflux disease develop Barrett's esophagus. We evaluated the association between Barrett's esophagus and multimers of an adipose-associated hormone, adiponectin.

methodsWe conducted a case-control study evaluating the associations between adiponectin (total, high-molecular-weight, and low-/medium-molecular-weight) and Barrett's esophagus within the Kaiser Permanente Northern California population. Patients with a new diagnosis of Barrett's esophagus (cases) were matched to patients with gastroesophageal reflux disease (GERD) without Barrett's esophagus and to population controls.

resultsComplete serologic and epidemiologic data were available for 284 cases, 294 GERD controls, and 285 population controls. Increasing adiponectin levels were a risk factor for Barrett's esophagus among patients with GERD (total adiponectin fourth vs first quartile odds ratio [OR], 1.96; 95% confidence interval [CI], 1.17-3.27; high-molecular-weight adiponectin OR, 1.65; 95% CI, 1.00-2.73; low-/medium-molecular-weight adiponectin OR, 2.18; 95% CI, 1.33-3.56), but not compared with population controls. The associations were significantly stronger among patients reporting frequent GERD symptoms and among smokers (P values interaction < .01).

conclusionsAdiponectin levels are associated positively with the risk of Barrett's esophagus among patients with GERD and among smokers, but not among population controls without GERD symptoms. Higher adiponectin concentrations either independently may contribute to the aberrant healing of esophageal injury into Barrett's esophagus or be a marker for other factors.

Indexed as

AdiponectinAdolescentAdultAgedBarrett EsophagusCaliforniaCase-Control StudiesGastroesophageal RefluxHumansMaleMiddle AgedRisk AssessmentYoung AdultAdiponectinAdipokinesAdiponectinBarrett’s EsophagusBMIEsophageal Adenocarcinoma

Identifiers

PMID25632808
PMCPMC4515407
OpenAlexW1976590110

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.